Home
Medicines
Active Ingredients
Companies
DHPC
Advanced Search
Adverse Event Reporting
Login
Search Medicine Database
Home
Medicines
Active Ingredients
Companies
DHPC
Advanced Search
Adverse Event Reporting
Login
menu
Home
Direct Healthcare Professional Communications
Browse DHPC Documents
Search
a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
s
t
u
v
w
x
y
z
0-9
all
all
(
7
results found)
Sort by:
Name A to Z
Date Last Updated:
Medicine
Status
DHPC Document Name
Additional Communications
Company
IMBRUVICA 140 mg, 280 mg, 420 mg and 560 mg film-coated tablets
No Recent Update
IMBRUVICA® (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events
COM
04/11/22
Janssen Sciences Ireland
Topamax 100mg film-coated tablets
No Recent Update
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
COM
19/10/22
Janssen Sciences Ireland
Topamax 200mg film-coated tablets
No Recent Update
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
COM
19/10/22
Janssen Sciences Ireland
Topamax 25mg film-coated tablet
No Recent Update
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
COM
19/10/22
Janssen Sciences Ireland
Topamax 50mg film-coated tablets
No Recent Update
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
COM
19/10/22
Janssen Sciences Ireland
Topamax Sprinkle 15mg
No Recent Update
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
COM
19/10/22
Janssen Sciences Ireland
Topamax Sprinkle 25mg
No Recent Update
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
COM
19/10/22
Janssen Sciences Ireland
Direct Healthcare Professional Communications
This medicine and its document have not been updated in the last 30 days.